Comparing the Molecular Pharmacological Properties of Existing β‐Blockers to Determine the Theoretically Most “Ideal” Anti‐Cancer β‐Blocker
Open Access
- 3 January 2026
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (1) , e70214
Abstract
There is increasing evidence, from cellular, animal and human epidemiological studies, linking β‐blockers with reductions in cancer growth and metastasis. Propranolol is the most investigated β‐blocker for cancer; although as many different off‐patent β‐blockers exist, there is little commercial incentive to drive comparative clinical trials. To minimize any chance of endogenous β‐agonist driven cancer growth or metastasis, theoretically, the “ideal” anti‐cancer β‐blocker would have high affinity, no partial agonism, and long duration of action at β2‐adrenoceptors (and for some cancers, additionally at β1 or β3‐AR). Using CHO cells stably expressing the wildtype and polymorphic variants of the human β1 and β1‐adrenoceptors, this study assessed 35 β‐blockers for the affinity and duration of binding (using 3 H‐CGP12177 whole cell binding) and intrinsic efficacy (CRE‐gene transcription). Despite high affinity, some β‐blockers had a short binding duration (e.g., alprenolol, bupranolol, levobunolol, nadolol and oxprenolol). Other compounds had substantial partial agonism (e.g., cyanopindolol, bucindolol, pindolol, pronethalol and xamoterol) and other compounds had a biphasic washout (e.g., bucindolol, timolol, carpindolol, and CGP12177) for reasons unknown. Considering all 3 factors, carazolol and ICI118551 may be more “ideal” than propranolol; however, carvedilol, with higher affinity and substantially longer duration of β2 (and β1) receptor binding than propranolol whilst maintaining low partial agonism, may be the most theoretically optimal. Furthermore, it is already widely used in cardiovascular medicine as an off‐patent tablet. Thus, carvedilol may have more optimal molecular pharmacological characteristics for an “anti‐cancer” β‐blocker than propranolol and could enter prospective comparative clinical trials without needing any further clinical workup.Keywords
Funding Information
- Wellcome Trust (086039/Z/08/Z)
- University of Nottingham
This publication has 80 references indexed in Scilit:
- Investigations into factors determining the duration of action of the β2‐adrenoceptor agonist, salmeterolBritish Journal of Pharmacology, 1993
- Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.1990
- Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of ?-adrenoceptor subtypes in the dissociation between blockade and stimulationNaunyn-Schmiedeberg's Archives of Pharmacology, 1984
- The effect of pindolol on the two years mortality after complicated myocardial infarction.1983
- A Randomized Trial of Propranolol in Patients With Acute Myocardial InfarctionJAMA, 1982
- EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1981
- An early intervention secondary prevention study with oxprenolol following myocardial infarctionEuropean Heart Journal, 1981
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- RANDOMISED PLACEBO-CONTROLLED TRIAL COMPARING OXPRENOLOL WITH DISOPYRAMIDE PHOSPHATE IN IMMEDIATE TREATMENT OF SUSPECTED MYOCARDIAL INFARCTIONThe Lancet, 1980
- COMPARISON OF SOME PROPERTIES OF PRONETHALOL AND PROPRANOLOLBritish Journal of Pharmacology and Chemotherapy, 1965